The Patent Finder

Lipid Formulations with Immunogens

GlaxoSmithKline Biologicals S.A.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 9 of these applications claim priority to application 13/808,080, filed Mar 14, 2013. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresPatent lifetimeUsedRemainingConfidence
US 11,638,693Vaccine for Eliciting Immune Response Comprising RNA Encoding an Immunogen and Lipid Formulations Comprising Mole Percentage of Lipids
In force
 · Medium confidence
UsedRemaining
GlaxoSmithKline Biologicals S.A.In forceMedium confidence
US 11,638,694Vaccine for Eliciting Immune Response Comprising Lipid Formulations and RNA Encoding Multiple Immunogens
In force
 · Medium confidence
GlaxoSmithKline Biologicals S.A.In forceMedium confidence
US 11,666,534Methods of Administering Lipid Formulations with Viral Immunogens
In force
 · Low confidence
GlaxoSmithKline Biologicals S.A.In forceLow confidence
US 11,766,401Methods of Administering Lipid Formulations with Immunogens
In force
 · High confidence
GlaxoSmithKline Biologicals S.A.In forceHigh confidence
US 11,786,467Lipid Formulations with Immunogens
In force
 · Low confidence
GlaxoSmithKline Biologicals S.A.In forceLow confidence
US 11,839,686Lipid Formulations with Viral Immunogens
In force
 · High confidence
GlaxoSmithKline Biologicals S.A.In forceHigh confidence
US 11,857,681Lipid Formulations with RNA Encoding Immunogens
In force
 · Medium confidence
GlaxoSmithKline Biologicals S.A.In forceMedium confidence
US 11,883,534Immunisation with Lipid Formulations with RNA Encoding Immunogens
In force
 · Medium confidence
GlaxoSmithKline Biologicals S.A.In forceMedium confidence
US 11,850,305Method of Making Lipid Formulations with RNA Encoding Immunogens
In force
 · Medium confidence
GlaxoSmithKline Biologicals S.A.In forceMedium confidence
Application 13/808,080Liposomes with Lipids Having an Advantageous Pka-Value for RNA Delivery
Abandoned
Abandoned Jan 13, 2023
GlaxoSmithKline Biologicals S.A.AbandonedAbandoned Jan 13, 2023
5 more records in this group · Pro
10 of 15 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 15.
Upgrade to Pro
9 of these are in force and held by GlaxoSmithKline Biologicals S.A..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited